Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 4/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 6/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LCT | P09848 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17792246 | 1.00 | MGAM (0.48) | MGAMFUCA1GBA1GAATDP1 | |
| SCHEMBL941940 | 0.77 | MGAM (0.42) | MGAMFUCA1GBA1GAATDP1 | |
| SCHEMBL12909426 | 0.77 | MGAM (0.42) | MGAMFUCA1GBA1GAATDP1 | |
| SCHEMBL20225057 | 0.77 | MGAM (0.42) | MGAMFUCA1GBA1GAATDP1 | |
| SCHEMBL14624899 | 0.74 | MGAM (0.58) | MGAMFUCA1GBA1GAATDP1 | |
| SCHEMBL4106580 | 0.74 | MGAM (0.58) | MGAMFUCA1GBA1GAATDP1 | |
| SCHEMBL14624581 | 0.74 | MGAM (0.58) | MGAMFUCA1GBA1GAATDP1 | |
| SCHEMBL13004948 | 0.74 | MGAM (0.58) | MGAMFUCA1GBA1GAATDP1 | |
| SCHEMBL13848042 | 0.74 | MGAM (0.58) | MGAMFUCA1GBA1GAATDP1 | |
| SCHEMBL2438771 | 0.74 | MGAM (0.58) | MGAMFUCA1GBA1GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | MGAM 97/4885FUCA1 1506/4885GBA1 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.